参考文献/References:
[1]邹小农,贾漫漫,王鑫,等.《2020全球癌症报告》要点解读[J].中国胸心血管外科临床杂志,2021,28(1):11-18.[2]Bashraheel SS,Domling A,Goda SK.Update on targeted cancer therapies,single or in combination,and their fine tuning for precision medicine[J].Biomed Pharmacother,2020,125:110009.[3]Colli LM,Machiela MJ,Zhang H,et al.Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management[J].Cancer Res,2017,77(13):3666-3671.[4]Wu L,Qu X.Cancer biomarker detection:recent achievements and challenges[J].Chem Soc Rev,2015,44(10):2963-2997.[5]Sanchez Calle A,Kawamura Y,Yamamoto Y,et al.Emerging roles of long non-coding RNA in cancer[J].Cancer Sci,2018,109(7):2093-2100.[6]Zhang H,Zhu X,Liu X,et al.Long non-coding RNA FOXD3-AS1 regulates the expression and secretion of IL-25 in nasal epithelial cells to inhibit Th2 type immunoreaction in allergic rhinitis[J].Mol Cell Biochem,2020,473(1-2):239-246.[7]Abel EV,Aplin AE.FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells[J].Cancer Res,2010,70(7):2891-2900.[8]Ji T,Zhang Y,Wang Z,et al.FOXD3-AS1 suppresses the progression of non-small cell lung cancer by regulating miR-150/SRCIN1axis[J].Cancer Biomark,2020,29(3):417-427.[9]Zeng ZL,Zhu HK,He LF,et al.Highly expressed lncRNA FOXD3-AS1 promotes non-small cell lung cancer progression via regulating miR-127-3p/mediator complex subunit 28 axis[J].Eur Rev Med Pharmacol Sci,2020,24(5):2525-2538.[10]Zheng J,Peng B,Zhang Y,et al.FOXD3-AS1 Knockdown Suppresses Hypoxia-Induced Cardiomyocyte Injury by Increasing Cell Survival and Inhibiting Apoptosis via Upregulating Cardioprotective Molecule miR-150-5p In Vitro[J].Front Pharmacol,2020,11:1284.[11]Huang H,Li L,Wen K.Interactions between long non-coding RNAs and RNA-binding proteins in cancer (Review)[J].Oncol Rep,2021,46(6):256.[12]Zhou RS,Zhang EX,Sun QF,et al.Integrated analysis of lncRNA-miRNA-mRNA ceRNA network in squamous cell carcinoma of tongue[J].BMC Cancer,2019,19(1):779.[13]Li Z,An X,Zhu T,et al.Discovering and Constructing ceRNA-miRNA-Target Gene Regulatory Networks during Anther Development in Maize[J].Int J Mol Sci,2019,20(14):3480.[14]Chen X,Gao J,Yu Y,et al.LncRNA FOXD3-AS1 promotes proliferation,invasion and migration of cutaneous malignant melanoma via regulating miR-325/MAP3K2[J].Biomed Pharmacother,2019,120:109438.[15]Wan N,Yang W,Cheng H,et al.FOXD3-AS1 Contributes to the Progression of Melanoma Via miR-127-3p/FJX1 Axis[J].Cancer Biother Radiopharm,2020,35(8):596-604.[16]Wu Q,Shi M,Meng W,et al.Long noncoding RNA FOXD3-AS1 promotes colon adenocarcinoma progression and functions as a competing endogenous RNA to regulate SIRT1 by sponging miR-135a-5p[J].J Cell Physiol,2019,234(12):21889-21902.[17]Chen Y,Gao H,Li Y.Inhibition of LncRNA FOXD3-AS1 suppresses the aggressive biological behaviors of thyroid cancer via elevating miR-296-5p and inactivating TGF-β1/Smads signaling pathway[J].Mol Cell Endocrinol,2020,500:110634.[18]Ma WG,Shi SM,Chen L,et al.SP1-induced lncRNA FOXD3-AS1 contributes to tumorigenesis of cervical cancer by modulating the miR-296-5p/HMGA1 pathway[J].J Cell Biochem,2021,122(2):235-248.[19]Wang Y,Luo W,Wang Y.PARP-1 and its associated nucleases in DNA damage response[J].DNA Repair (Amst),2019,81:102651.[20]Ray Chaudhuri A,Nussenzweig A.The multifaceted roles of PARP1 in DNA repair and chromatin remodelling[J].Nat Rev Mol Cell Biol,2017,18(10):610-621.[21]Zhao X,Li D,Huang D,et al.Risk-Associated Long Noncoding RNA FOXD3-AS1 Inhibits Neuroblastoma Progression by Repressing PARP1-Mediated Activation of CTCF[J].Mol Ther,2018,26(3):755-773.[22]陈振华.长链非编码RNA FOXD3-AS1在脑胶质瘤中的表达及功能研究[D].上海:第二军医大学,2016.[23]Liu C,Zhang M,Zhao J,et al.LncRNA FOXD3-AS1 Mediates AKT Pathway to Promote Growth and Invasion in Hepatocellular Carcinoma Through Regulating RICTOR[J].Cancer Biother Radiopharm,2020,35(4):292-300.[24]郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,41(1):19-28.[25]Guan Y,Bhandari A,Xia E,et al.lncRNA FOXD3-AS1 is associated with clinical progression and regulates cell migration and invasion in breast cancer[J].Cell Biochem Funct,2019,37(4):239-244.[26]Masuda S.Pathological examination of breast cancer biomarkers: current status in Japan[J].Breast Cancer,2016,23(4):546-551.[27]Zeng ZL,Zhu HK,He LF,et al.Highly expressed lncRNA FOXD3-AS1 promotes non-small cell lung cancer progression via regulating miR-127-3p/mediator complex subunit 28 axis[J].Eur Rev Med Pharmacol Sci,2020,24(5):2525-2538.[28]张心武,张寅斌,张迪,等.FOXD3-AS1在进展期远端胃癌中的表达及临床意义[J].中国中西医结合消化杂志,2020,28(5):356-359.[29]Chen ZH,Hu HK,Zhang CR,et al.Down-regulation of long non-coding RNA FOXD3 antisense RNA 1 (FOXD3-AS1) inhibits cell proliferation,migration,and invasion in malignant glioma cells[J].Am J Transl Res,2016,8(10):4106-4119.[30]Zhang E,Li C,Xiang Y.LncRNA FOXD3-AS1/miR-135a-5p function in nasopharyngeal carcinoma cells[J].Open Medicine,2020,15(1):1193-1201.
相似文献/References:
[1]袁东方,张刚刚.恶性肿瘤病历主要诊断选择思路分析[J].医学信息,2018,31(07):28.[doi:10.3969/j.issn.1006-1959.2018.07.010]
YUAN Dong-fang,ZHANG Gang-gang.Analysis of Main Diagnostic Options for Malignant Tumor Records[J].Medical Information,2018,31(10):28.[doi:10.3969/j.issn.1006-1959.2018.07.010]
[2]张国锐,贾 林,赵 丹,等.老年维持血液透析患者恶性肿瘤发病的相关因素分析[J].医学信息,2022,35(10):113.[doi:10.3969/j.issn.1006-1959.2022.10.027]
ZHANG Guo-rui,JIA Lin,ZHAO Dan,et al.Analysis of Related Factors of Malignant Tumor in Elderly Maintenance Hemodialysis Patients[J].Medical Information,2022,35(10):113.[doi:10.3969/j.issn.1006-1959.2022.10.027]
[3]姜天奇,张洪亮.原发性肝癌的中西医治疗现状[J].医学信息,2019,32(13):35.[doi:10.3969/j.issn.1006-1959.2019.13.012]
JIANG Tian-qi,ZHANG Hong-liang.Current Status of Treatment of Primary Liver Cancer with Traditional Chinese Medicine and
Western Medicine[J].Medical Information,2019,32(10):35.[doi:10.3969/j.issn.1006-1959.2019.13.012]
[4]何 静.上皮性卵巢癌化学治疗的研究[J].医学信息,2019,32(18):24.[doi:10.3969/j.issn.1006-1959.2019.18.009]
HE Jing.Chemotherapy of Epithelial Ovarian Cancer[J].Medical Information,2019,32(10):24.[doi:10.3969/j.issn.1006-1959.2019.18.009]
[5]梁春玲,杨文珊.消化道恶性肿瘤的临床分析[J].医学信息,2019,32(18):124.[doi:10.3969/j.issn.1006-1959.2019.18.041]
LIANG Chun-ling,YANG Wen-shan.Clinical Analysis of Malignant Tumors of the Digestive Tract[J].Medical Information,2019,32(10):124.[doi:10.3969/j.issn.1006-1959.2019.18.041]
[6]陈云娥,李 璠,张子怡,等.营养支持治疗对终末期恶性肿瘤患者临床结局影响的Meta分析[J].医学信息,2019,32(19):63.[doi:10.3969/j.issn.1006-1959.2019.19.019]
CHEN Yun-e,LI Fan,ZHANG Zi-yi,et al.Meta-analysis of Effect of Nutritional Support Therapy on Clinical Outcome of Patients with Terminal-stage Malignant Tumor[J].Medical Information,2019,32(10):63.[doi:10.3969/j.issn.1006-1959.2019.19.019]
[7]杜鑫荣.超声造影在肝实质性肿块诊断及鉴别中的临床价值[J].医学信息,2019,32(19):176.[doi:10.3969/j.issn.1006-1959.2019.19.059]
DU Xin-rong.Clinical Value of Contrast-enhanced Ultrasonography in the Diagnosis and Differential Diagnosis of Liver Mass[J].Medical Information,2019,32(10):176.[doi:10.3969/j.issn.1006-1959.2019.19.059]
[8]易亭伍,邓窈窕,宿向东.恶性肿瘤患者及家属信息需求现状的多中心研究[J].医学信息,2019,32(22):72.[doi:10.3969/j.issn.1006-1959.2019.22.023]
YI Ting-wu,DENG Yao-tiao,SU Xiang-dong.Multi-center Study on the Status of Information Needs of Patients with Malignant Tumors and their Families[J].Medical Information,2019,32(10):72.[doi:10.3969/j.issn.1006-1959.2019.22.023]
[9]赵博志,赵国林,杨 敏,等.乳腺鳞状细胞癌的临床诊疗研究[J].医学信息,2020,33(03):46.[doi:10.3969/j.issn.1006-1959.2020.03.014]
ZHAO Bo-zhi,ZHAO Guo-lin,YANG Min,et al.Clinical Diagnosis and Treatment of Squamous Cell Carcinoma of the Breast[J].Medical Information,2020,33(10):46.[doi:10.3969/j.issn.1006-1959.2020.03.014]
[10]吴鑫阳,方明治.中医药治疗恶性肿瘤相关性贫血现状[J].医学信息,2020,33(06):31.[doi:10.3969/j.issn.1006-1959.2020.06.010]
ZHANG Zhe.Status of Treatment of Malignant Tumor-related Anemia with Traditional Chinese Medicine[J].Medical Information,2020,33(10):31.[doi:10.3969/j.issn.1006-1959.2020.06.010]